NEWS & UPDATE
New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment
May 27, 2022 — 5 min read
NEWS & UPDATE
New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment
May 27, 2022 — 5 min read
NEWS & UPDATE
Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment–Published in the European Journal of Cancer
May 19, 2022 — 5 min read
NEWS & UPDATE
Lunit to Present 11 Abstracts at the 2022 ASCO Annual Meeting
Apr 28, 2022 — 5 min read
NEWS & UPDATE
Lunit AI solution for PD-L1 expression analysis receives CE mark
Apr 27, 2022 — 3 min read
Medical AI Startup Lunit gets Preliminary Approval to go Public on KOSDAQ
New Studies at AACR 2022 Highlight Lunit SCOPE’s Immune Phenotyping Capabilities
Lunit AI Demonstrates Accuracy in Practical Assessment of Cancer Tissue-Findings to Be Presented at USCAP 2022
Breakthrough Study Validates Artificial Intelligence as a Novel Biomarker in Predicting Immunotherapy Response - Published in Journal of Clinical Oncology
Baheya Foundation, Egypt’s Premier Destination for Breast Cancer, Adopts Lunit AI to Enhance Early Screening
Lunit to Showcase Chest and Breast Radiology AI in Arab Health 2022
Lunit Obtains MDSAP Certificate, Granted Fast-Track Regulatory Process in Major Countries
Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Logo System
Lunit LogoAll LogosCompany Introduction
EN - Lunit IntroductionKR - Lunit IntroductionProducts Image
Lunit INSIGHTLunit SCOPE